Convertible loan term payment settled in shares – 29 Aug 2024
Reference is made to IDEX Biometrics ASA’s notice on 28 December 2023 about issuance of a convertible bond. Under the terms of the loan, IDEX Biometrics may elect to settle any amortization and/or interest payments on the loan, in cash or shares. The prospectus published earlier today enables the company to issue the full theoretical maximum number of shares needed to repay the loan.
IDEX Biometrics ASA has today issued 9,123,333 shares in the company to settle a term payment on the convertible loan amounting to NOK 5,474,000.-. Following the settlement of the instant term payment, the loan balance amounts to NOK 66,640,000.
The increase in capital will be registered soonest and the shares delivered immediately after. Following issuance of the shares, IDEX Biometrics ASA’s share capital is NOK 50,812,483.20, divided into 338,749,888 shares, each with a nominal value of NOK 0.15.
* Volume-weighted average price
Contact person
Marianne Bøe, Head of Investor Relations
E-mail: [email protected]
Tel: +47 9180 0186
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.
For more information, visit www.idexbiometrics.com
About this notice
This notice was issued by Erling Svela, Vice president of finance, on 29 August 2024 at 21:50 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to section 5‑8 of the Norwegian Securities Trading Act (STA) and published in accordance with section 5‑12 of the STA.
